T1	Participants 40 74	patients with atrial fibrillation.
T2	Participants 103 136	after conversion to sinus rhythm.
T3	Participants 296 329	patients with atrial fibrillation
T4	Participants 427 519	Patients who had symptomatic atrial fibrillation for > 48 hours but < 6 months were eligible
T5	Participants 589 625	Patients were admitted to a hospital
T6	Participants 630 747	randomly assigned to receive either azimilide 125 mg or a matched placebo twice daily for 3 days and then once daily.
T7	Participants 748 894	Patients who were in sinus rhythm spontaneously or had sinus rhythm restored by electric cardioversion on day 4 were discharged from the hospital.
T8	Participants 1100 1139	patients with structural heart disease.
T9	Participants 1234 1332	446 patients were randomized in the study; 314 were in the subgroup with structural heart disease.
T10	Participants 1827 1928	patients with structural heart disease who were in atrial fibrillation and converted to sinus rhythm.
